NETRI PRESENTATION.
A new scale.
Based on 10 years of work in academic research, NETRI was founded in June 2018 in Lyon. Considered as a TechBio, NETRI develops so-called organs-on-chip technologies that, coupled with Artificial Intelligence, predict the human effect of a drug candidate.
Located in the heart of Lyon's Gerland Biodistrict, NETRI manufactures and operates its devices in its production unit, using techniques derived from the microelectronics industry, cell culture automation and Artificial Intelligence.
•1100m² of production units.
•500m² of offices.
•35 employees: 12 PhDs within a multidisciplinary team (engineering, biology and digital).
NETRI AMBITION & MISSION.
NETRI's ambition: Digitizing Human Biology.
NETRI is pioneering the digitization of human biology by harnessing the natural intelligence of neurons. These biological data processors continuously transmit information about the state of the body’s organs through electrical signals — a flow of data that NETRI transforms into actionable digital signatures. Since 2018, the company has been developing technologies that replicate human innervation using neural stem cells, enabling the recording and analysis of these signals in response to pharmaceutical compounds, chemicals, or human fluids.
NETRI's ambition is to massively populate its digital libraries in its priority application areas, enabling unprecedented accuracy in predicting efficacy, toxicology, and disease diagnostics.
To realize this vision, NETRI is scaling its technologies, industrializing cell culture processes, and accelerating its international expansion — delivering not only innovative devices but also high-value standardized data that reshape the future of drug development
NETRI's mission: Support human health improvement.
NETRI’s mission is to support human health improvement through the discriminating power of the nervous system. Through its Neuron-as-a-Sensor (NaaS) suite — a combination of proprietary hardware, software, biological models, and data pipelines — the company delivers cutting-edge solutions to assess compound safety, efficacy, and diagnostic potential.
By replicating the body’s natural neural communication and leveraging automation-ready, compartmentalized platforms, NETRI offers insights into drug efficacy, toxicity and repositioning, rare disease mechanisms, and clinical scheduling strategies.
KEY FIGURES & TIMELINE.
Key figures.
• 2018: NETRI founded.
• 2023: Launch of NeuroFluidics MEA (First worldwide MEA-compartmentalized) and Pain platform.
• 2025: Inauguration of France's first organ-on-a-chip production plant.
• 33 People including 12 PhDs.
Timeline.
NETRI PLANT.
OF HCS PHARMA.
ORGANS-ON-CHIP
INITIATIVE.
INNOVATION AWARD.
& PAIN MODEL.
AXOTOMY MODEL.
CHARACTERIZATION.
NEW ARCHITECTURES
& FORMAT.
& COMMERCIALIZATION.
• Set up in the competitiveness cluster Lyonbiopôle, in the Gerland biodistrict.
• First commercial unit chips.
